JP2021531814A - インターフェロン−ガンマバイアス型アゴニスト - Google Patents

インターフェロン−ガンマバイアス型アゴニスト Download PDF

Info

Publication number
JP2021531814A
JP2021531814A JP2021505349A JP2021505349A JP2021531814A JP 2021531814 A JP2021531814 A JP 2021531814A JP 2021505349 A JP2021505349 A JP 2021505349A JP 2021505349 A JP2021505349 A JP 2021505349A JP 2021531814 A JP2021531814 A JP 2021531814A
Authority
JP
Japan
Prior art keywords
amino acid
ifn
polypeptide
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021505349A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020028275A5 (https=
JP2021531814A5 (https=
Inventor
クリストファー ガルシア ケナン
ルイス メンドーザ ジュアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2021531814A publication Critical patent/JP2021531814A/ja
Publication of JPWO2020028275A5 publication Critical patent/JPWO2020028275A5/ja
Publication of JP2021531814A5 publication Critical patent/JP2021531814A5/ja
Priority to JP2024095641A priority Critical patent/JP2024137947A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021505349A 2018-07-30 2019-07-29 インターフェロン−ガンマバイアス型アゴニスト Ceased JP2021531814A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024095641A JP2024137947A (ja) 2018-07-30 2024-06-13 インターフェロン－ガンマバイアス型アゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712128P 2018-07-30 2018-07-30
US62/712,128 2018-07-30
PCT/US2019/043977 WO2020028275A1 (en) 2018-07-30 2019-07-29 Interferon-gamma biased agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024095641A Division JP2024137947A (ja) 2018-07-30 2024-06-13 インターフェロン－ガンマバイアス型アゴニスト

Publications (3)

Publication Number Publication Date
JP2021531814A true JP2021531814A (ja) 2021-11-25
JPWO2020028275A5 JPWO2020028275A5 (https=) 2022-08-08
JP2021531814A5 JP2021531814A5 (https=) 2022-08-08

Family

ID=69230882

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021505349A Ceased JP2021531814A (ja) 2018-07-30 2019-07-29 インターフェロン−ガンマバイアス型アゴニスト
JP2024095641A Pending JP2024137947A (ja) 2018-07-30 2024-06-13 インターフェロン－ガンマバイアス型アゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024095641A Pending JP2024137947A (ja) 2018-07-30 2024-06-13 インターフェロン－ガンマバイアス型アゴニスト

Country Status (7)

Country Link
US (1) US12410226B2 (https=)
EP (1) EP3830115A4 (https=)
JP (2) JP2021531814A (https=)
AU (1) AU2019313339A1 (https=)
CA (1) CA3108066A1 (https=)
MX (1) MX2021001165A (https=)
WO (1) WO2020028275A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028275A1 (en) 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
WO2022212525A2 (en) 2021-03-30 2022-10-06 City Of Hope Car t cell therapy and ifn gamma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251619A1 (en) * 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2014106843A2 (en) * 2013-01-01 2014-07-10 Inuitive Ltd. Method and system for light patterning and imaging
WO2018077893A1 (en) * 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
JP2969461B2 (ja) 1988-07-23 1999-11-02 株式会社林原生物化学研究所 ヒトγ−インターフェロンとその製造方法並びに用途
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
DE19535853C2 (de) * 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
SK8292002A3 (en) 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
JP2004522803A (ja) 2001-06-29 2004-07-29 マキシゲン・エイピーエス インターフェロン製剤
AU2003239774A1 (en) * 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
CA2809747C (en) 2010-08-30 2018-05-01 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
WO2020028275A1 (en) 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
EP3883585A4 (en) 2018-11-20 2022-12-14 Innovative Cellular Therapeutics Holdings, Ltd. MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251619A1 (en) * 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2014106843A2 (en) * 2013-01-01 2014-07-10 Inuitive Ltd. Method and system for light patterning and imaging
WO2018077893A1 (en) * 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 567, JPN6023027217, 7 March 2019 (2019-03-07), pages 56 - 60, ISSN: 0005468469 *

Also Published As

Publication number Publication date
CA3108066A1 (en) 2020-02-06
MX2021001165A (es) 2021-07-15
WO2020028275A1 (en) 2020-02-06
US20210309707A1 (en) 2021-10-07
US12410226B2 (en) 2025-09-09
EP3830115A1 (en) 2021-06-09
EP3830115A4 (en) 2022-08-10
JP2024137947A (ja) 2024-10-07
AU2019313339A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
AU2023203727B2 (en) Biologically relevant orthogonal cytokine/receptor pairs
US12060401B2 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
US12440540B2 (en) IL-2 orthologs and methods of use
JP6853317B2 (ja) 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン
JP2024079749A (ja) インターロイキン－２の部分アゴニスト
JP6441867B2 (ja) インターロイキン２のスーパーアゴニストおよびアンタゴニスト
TWI488864B (zh) 用於治療癌症及慢性感染之具有促效劑活性之介白素－２（ｉｌ－２）衍生物多肽
KR20170068553A (ko) 인터류킨-15 조성물 및 이의 용도
JP2024137947A (ja) インターフェロン－ガンマバイアス型アゴニスト
EP1537145A1 (en) Pharmaceutical compositions and medical treatments comprising notch ligand proteins
JP7830450B2 (ja) 修飾されたｉｌ－２分子及びその用途
EP4419555A2 (en) Human il-12p40 variants and uses thereof
CA2560525A1 (en) Immunosuppressive cytokine
JP2000515016A (ja) 高親和性インターロイキン―４突然変異タンパク質
KR20220139293A (ko) 인터류킨 2 키메라 구축물
JP2024543991A (ja) Ｉｌ１０バリアントおよびその使用
US20050069987A1 (en) Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
Dumont The interleukin-1 families of cytokines and receptors: therapeutic potential for immunomodulation and the treatment of inflammatory disorders
IL324787A (en) Il10 inverted monomers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240618

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240809

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250325